OR
ORIC Pharmaceuticals, Inc.
ORIC · NASDAQ
$12.67 -2.20% (-$0.29)
1M -5.87%
Market Cap $1.31B
P/E Ratio -
Div. Yield -
ROE 35.35%
Bulios Fair Price
$10.47
17.4% downside
Current Price
$12.67
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ORIC is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
59 /100
Fair P/B 3.44x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 20.01%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
0 /100
Poor ROIC 40.32%
ROE 35.35%
Asset turnover 0.00x
Debt
100 /100
Low Debt/Equity 0.01x
Current ratio 13.19x
Int. coverage N/A
Stability
76 /100
Stable Beta 0.99x
EPS volatility 6.52%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ORIC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jacob Chacko
Employees
111
Headquarters
South San Francisco
Upcoming events
12 NOV
Earnings
Upcoming earnings report